MRTX News and Press, Mirati Therapeutics Inc. From 08/08/23

2023-08-08 20:51:10 ET Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Conference Call August 08, 2023 04:30 PM ET Company Participants Ryan Asay - Vice President-Corporate Affairs Chuck Baum - President, Founder & Interim Chief Executive Officer Alan Sandl...

2023-08-08 16:48:54 ET Mirati Therapeutics press release ( NASDAQ: MRTX ): Q2 GAAP EPS of -$3.04 beats by $0.17 . Revenue of $13.69M (+155.4% Y/Y) beats by $0.07M . Cash, cash equivalents and short-term investments of approximately $779.4 million as of June 30,...

Mirati Therapeutics Announces Proposed Public Offering PR Newswire SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, today announced that it intends to offer and sell $250.0 million of...

Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates PR Newswire Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥...

Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek PR Newswire Charles M. Baum , M.D., Ph.D. assumes role of interim CEO SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a...

Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023 PR Newswire SAN DIEGO , July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, ...

2023-07-25 09:00:00 ET Summary Mirati Therapeutics' expansion plan faces setback as European Medicines Agency denies authorization for lung cancer drug Krazati. Despite the EU setback, MRTX remains resolute in its commitment to Krazati, with promising results from Phase 2 trials. ...

NEW YORK, NY / ACCESSWIRE / July 21, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mirati Therapeutics, Inc. ("Mirati" or "the Company") (NASDAQ:MRTX). Investors who purchased Mirati securities are encouraged to obtain additional infor...

2023-07-21 10:22:31 ET Gainers: Quoin Pharmaceuticals ( QNRX ) +45% . Evelo Biosciences ( EVLO ) +24% . Biodexa Pharmaceuticals ( BDRX ) +19% . LifeMD ( LFMD ) +13% . BIMI International Medical ( BIMI ) +12% . Losers: ...

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of KRAZATI (adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRAS G12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , July 21, 2023 /PRNews...